-- ATR 1072 is the company's first precision cardiology program to enter the clinic --

-- Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --

SAN DIEGO, July 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application allowing the Company to move forward with its Corventis™ Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome.